BioNTech (NASDAQ:BNTX) Trading Down 2.4% – Time to Sell?

Shares of BioNTech SE (NASDAQ:BNTX) fell 2.4% during mid-day trading on Tuesday . The company traded as low as $100.19 and last traded at $99.85. 69,811 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 856,247 shares. The stock had previously closed at $102.34.

Wall Street Analysts Forecast Growth

Several analysts have commented on BNTX shares. Morgan Stanley dropped their target price on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a research report on Tuesday, March 11th. Truist Financial started coverage on BioNTech in a research note on Friday, January 10th. They issued a “buy” rating and a $172.00 price target for the company. Canaccord Genuity Group reissued a “buy” rating and set a $171.44 price objective on shares of BioNTech in a research note on Tuesday, March 11th. Citigroup began coverage on shares of BioNTech in a research note on Thursday, March 13th. They issued a “buy” rating and a $145.00 target price for the company. Finally, BMO Capital Markets lifted their price target on shares of BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $143.44.

BioNTech Stock Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The stock has a 50-day moving average of $104.24 and a 200-day moving average of $111.51. The firm has a market cap of $23.55 billion, a price-to-earnings ratio of -46.72 and a beta of 1.07.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.90 earnings per share. As a group, analysts anticipate that BioNTech SE will post -3.88 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Several hedge funds have recently modified their holdings of the stock. Jones Financial Companies Lllp grew its stake in shares of BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after buying an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. grew its holdings in BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after purchasing an additional 700 shares during the period. Allianz SE acquired a new position in BioNTech during the fourth quarter worth approximately $90,000. GAMMA Investing LLC raised its stake in BioNTech by 48.2% in the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after buying an additional 300 shares during the period. Finally, Generali Investments CEE investicni spolecnost a.s. acquired a new stake in shares of BioNTech in the fourth quarter valued at approximately $137,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.